Supplementary Table S2 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)
Year: 2026
Type: supplementary-materials
Abstract: Supplementary Table 2: Representativeness of Study Participants
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7165037648